Keytruda is a medication that is used to treat various types of cancer. According to Drug Patent Watch [1], the wholesale acquisition cost (WAC) of Keytruda is $13,343.40 per 200 mg vial, as of October 2021. The actual cost of the medication may vary depending on factors such as insurance coverage, the dosage prescribed, and the length of treatment.

Merck, the manufacturer of Keytruda, offers financial assistance programs to eligible patients who are prescribed Keytruda [2]. These programs include co-pay assistance, free medication for eligible uninsured patients, and patient assistance programs. The eligibility criteria for these programs vary, and patients are encouraged to contact Merck for more information.

According to Axios [3], Keytruda is one of the best-selling drugs in the world, with global sales of $16.2 billion in 2020. The high cost of Keytruda has been a topic of controversy, with some critics arguing that the drug is overpriced. However, Merck has defended the price of Keytruda, stating that it reflects the significant investment in research and development that went into creating the medication.

In conclusion, the wholesale acquisition cost of Keytruda is $13,343.40 per 200 mg vial, as of October 2021. However, the actual cost of the medication may vary depending on various factors. Merck offers financial assistance programs to eligible patients, and Keytruda is one of the best-selling drugs in the world, with global sales of $16.2 billion in 2020.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/financial-support/
[3] https://www.axios.com/2021/10/29/keytruda-sales-merck-drug-prices